Published in J Biol Chem on March 15, 1991
The plasminogen activator/plasmin system. J Clin Invest (1991) 4.20
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (2004) 1.70
The importance of cysteine cathepsin proteases for placental development. J Mol Med (Berl) (2006) 1.54
Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res (2009) 1.35
Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell (2005) 1.35
Imaging proteolysis by living human breast cancer cells. Neoplasia (2001) 1.27
Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res (2008) 1.20
Urokinase and macrophages in tumour angiogenesis. Br J Cancer (1995) 1.19
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 1.14
Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res (2011) 1.07
Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells. Mol Imaging (2009) 1.05
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Mol Biol Cell (2008) 1.03
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax (1999) 0.90
Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes. J Biol Chem (2013) 0.88
Lysosomal cysteine endopeptidases mediate interleukin 1-stimulated cartilage proteoglycan degradation. Biochem J (1992) 0.87
The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J (2003) 0.86
Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy? Clin Mol Pathol (1995) 0.83
Oxygen-glucose deprivation (OGD) and interleukin-1 (IL-1) differentially modulate cathepsin B/L mediated generation of neuroprotective perlecan LG3 by neurons. Brain Res (2011) 0.83
Proteinases and their inhibitors in liver cancer. World J Hepatol (2009) 0.81
In vivo inhibition of cysteine proteinases delays the onset of growth of human pancreatic cancer explants. Br J Cancer (2000) 0.80
A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. PLoS Pathog (2013) 0.80
Cathepsin B is up-regulated and mediates extracellular matrix degradation in trabecular meshwork cells following phagocytic challenge. PLoS One (2013) 0.80
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer (1993) 0.79
Plasma cathepsin L: a prognostic marker for pancreatic cancer. World J Gastroenterol (2014) 0.75
The appearance and possible role of plasminogen activator of urokinase type (u-PA) activity in the cornea related to soft contact lens wear in rabbits. Doc Ophthalmol (1998) 0.75
Assays of glutathione peroxidase. Methods Enzymol (1984) 6.76
Antigenic variability of Borrelia burgdorferi. Ann N Y Acad Sci (1988) 5.02
Health and mental health problems of homeless men and women in Baltimore. JAMA (1989) 4.29
One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry (1988) 4.13
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol (2001) 4.09
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry (1984) 3.75
Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit (2009) 3.32
Comparison of the lay Diagnostic Interview Schedule and a standardized psychiatric diagnosis. Experience in eastern Baltimore. Arch Gen Psychiatry (1985) 3.18
A population of fast radio bursts at cosmological distances. Science (2013) 3.03
Reduction of polygalacturonase activity in tomato fruit by antisense RNA. Proc Natl Acad Sci U S A (1988) 2.75
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene (2000) 2.71
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol (2000) 2.58
Mental health and social characteristics of the homeless: a survey of mission users. Am J Public Health (1986) 2.50
One-month prevalence of mental disorders in the United States and sociodemographic characteristics: the Epidemiologic Catchment Area study. Acta Psychiatr Scand (1993) 2.49
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol (1992) 2.37
Do we need better prognostic factors in node-negative breast cancer? Pro:. Eur J Cancer (2000) 2.28
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry (1984) 2.26
Nucleotide sequence of a gene encoding the Borrelia burgdorferi flagellin. Nucleic Acids Res (1989) 2.21
Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation (1996) 2.20
The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seylers Z Physiol Chem (1982) 2.14
Glutathione peroxidase: a selenoenzyme. FEBS Lett (1973) 2.13
Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med (2001) 2.12
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res (2001) 2.06
Influence of Nitrate and Ammonia on Photosynthetic Characteristics and Leaf Anatomy of Moricandia arvensis. Plant Physiol (1982) 2.02
Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol (1999) 2.02
Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett (1991) 2.02
Transformation of a star into a planet in a millisecond pulsar binary. Science (2011) 2.01
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat (1993) 1.97
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res (2006) 1.79
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost (1997) 1.78
Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A (1997) 1.76
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst (2001) 1.71
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med (1999) 1.70
[Reliable micromethod for determination of the protein content in tissue homogenates]. Acta Biol Med Ger (1975) 1.69
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood (1994) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology (2001) 1.66
A double-pulsar system: a rare laboratory for relativistic gravity and plasma physics. Science (2004) 1.66
The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe Seylers Z Physiol Chem (1982) 1.64
An increased estimate of the merger rate of double neutron stars from observations of a highly relativistic system. Nature (2003) 1.62
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol (2009) 1.58
An experiment to change detection and management of mental morbidity in primary care. Med Care (1987) 1.57
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
Crystal structure of the first dissimilatory nitrate reductase at 1.9 A solved by MAD methods. Structure (1999) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet (1994) 1.56
Psychiatric need and demand in a prepaid group practice program. Am J Public Health Nations Health (1966) 1.54
The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology (1999) 1.53
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol (2003) 1.53
Therapeutic passive vaccination against chronic Lyme disease in mice. Proc Natl Acad Sci U S A (1997) 1.50
Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ (2002) 1.50
Role conceptions of baccalaureate nurses and success in hospital nursing. Nurs Res (1970) 1.49
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett (1999) 1.46
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost (1991) 1.46
The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program. Acta Psychiatr Scand (1989) 1.46
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
A preliminary evaluation of the Gonozyme test. Sex Transm Dis (1984) 1.43
An improved coupled test procedure for glutathione peroxidase (EC 1-11-1-9-) in blood. Z Klin Chem Klin Biochem (1974) 1.43
Intermediate use of triazolam: a sleep laboratory study. J Int Med Res (1976) 1.42
Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography. Ultrasound Obstet Gynecol (1997) 1.41
Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol (2001) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Isolated spastic paraparesis leading to diagnosis of Friedreich's ataxia. J Neurol Neurosurg Psychiatry (2000) 1.40
[Magnet hospitals. 1988]. Pflege (2012) 1.39
Fusion of computed tomography data and optical 3D images of the dentition for streak artefact correction in the simulation of orthognathic surgery. Dentomaxillofac Radiol (2004) 1.38
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res (1994) 1.36
MAGE-A gene expression pattern in primary breast cancer. Cancer Res (2001) 1.34
A review of parameters for the bioelectrical characterization of breast tissue. Ann N Y Acad Sci (1999) 1.34
Pseudorabies virus in wild swine: a global perspective. Arch Virol (2011) 1.33
The amino-acid sequence of bovine glutathione peroxidase. Hoppe Seylers Z Physiol Chem (1984) 1.31
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol (1999) 1.30
Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC. Eur J Immunol (1999) 1.28
A strong magnetic field around the supermassive black hole at the centre of the Galaxy. Nature (2013) 1.27
Identifying sources of reporting error using measured food intake. Eur J Clin Nutr (2007) 1.26
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem (2008) 1.25
Aspects of androgen-dependent events as studied by antiandrogens. Recent Prog Horm Res (1970) 1.25
The primary structure of Cu-Zn superoxide dismutase from Photobacterium leiognathi: evidence for a separate evolution of Cu-Zn superoxide dismutase in bacteria. Hoppe Seylers Z Physiol Chem (1983) 1.24
Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol (1995) 1.24
A population of gamma-ray millisecond pulsars seen with the Fermi Large Area Telescope. Science (2009) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet (1989) 1.22